Published in AIDS Behav on March 01, 2014
A perfect storm: crack cocaine, HSV-2, and HIV among non-injecting drug users in New York City. Subst Use Misuse (2014) 0.92
Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013. Drug Alcohol Depend (2015) 0.82
Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs? J Addict Dis (2015) 0.80
Will "Combined Prevention" Eliminate Racial/Ethnic Disparities in HIV Infection among Persons Who Inject Drugs in New York City? PLoS One (2015) 0.75
Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduct J (2017) 0.75
HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA (1989) 6.68
Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet (2001) 5.28
The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health (2003) 3.61
Sexual harm reduction practices of HIV-seropositive gay and bisexual men: serosorting, strategic positioning, and withdrawal before ejaculation. AIDS (2005) 3.47
Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet (2010) 3.29
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction (2007) 3.08
Declining HIV/AIDS mortality in New York City. J Acquir Immune Defic Syndr (1999) 3.01
Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS (2005) 2.91
"Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001. J Acquir Immune Defic Syndr (2004) 2.90
HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health (2005) 2.62
Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. Am J Public Health (1998) 2.28
Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health (2006) 2.20
Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction (2013) 1.81
Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy (2007) 1.75
Racial/ethnic disparities in HIV infection among people who inject drugs: an international systematic review and meta-analysis. Addiction (2012) 1.55
Persistence and change in disparities in HIV infection among injection drug users in New York City after large-scale syringe exchange programs. Am J Public Health (2009) 1.49
HIV among drug users at Beth Israel Medical Center, New York City, the first 25 years. Subst Use Misuse (2011) 1.34
HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors. Drug Alcohol Depend (2010) 1.21
Antiretroviral therapy and declining AIDS mortality in New York City. Med Care (2003) 1.15
The NYC Condom: use and acceptability of New York City's branded condom. Am J Public Health (2009) 1.06
NYC condom use and satisfaction and demand for alternative condom products in New York City sexually transmitted disease clinics. J Urban Health (2011) 0.96
HIV/AIDS complacency and HIV infection among young men who have sex with men, and the race-specific influence of underlying HAART beliefs. Sex Transm Dis (2011) 0.92
Access to sterile syringes for injecting drug users in New York City: politics and perception (1984-2010). Subst Use Misuse (2011) 0.89
Injection drug users as social actors: a stigmatized community's participation in the syringe exchange programmes of New York City. AIDS Care (1998) 0.88
Use of the "NYC Condom" among people who use drugs. J Urban Health (2014) 0.82
Antiretroviral therapy and declining AIDS mortality in New York City. J Urban Health (2000) 0.81
Harm reduction and HIV-prevention among injecting drug users in Australia: an international comparison. Can Bull Med Hist (2007) 0.81
Current and emerging research needs in studying the NYC HIV-drug use epidemic. Subst Use Misuse (2011) 0.78
Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet (1999) 8.91
Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA (1995) 4.88
Widespread dissemination of a drug-susceptible strain of Mycobacterium tuberculosis. J Infect Dis (1997) 2.31
Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin Infect Dis (1992) 2.29
Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex Transm Infect (2006) 2.00
High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol (1996) 1.81
Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health (2000) 1.78
Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol Biochem Behav (1997) 1.51
The protective effect of AIDS-related behavioral change among injection drug users: a cross-national study. WHO Multi-Centre Study of AIDS and Injecting Drug Use. Am J Public Health (1996) 1.51
A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis (2001) 1.46
Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis (2005) 1.35
Predictors of accidental fatal drug overdose among a cohort of injection drug users. Am J Public Health (2001) 1.33
Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol (1998) 1.31
Using a jail-based survey to monitor HIV and risk behaviors among Seattle area injection drug users. J Urban Health (2001) 1.21
Association of galanin haplotypes with alcoholism and anxiety in two ethnically distinct populations. Mol Psychiatry (2006) 1.18
Provision of influenza and pneumococcal vaccines to injection drug users at a syringe exchange. J Subst Abuse Treat (2000) 1.16
Catheter-related bacteremia due to Streptomyces in a patient receiving holistic infusions. Emerg Infect Dis (2001) 1.15
Prevalence and risk factors for positive tuberculin skin tests among active drug users at a syringe exchange program. Int J Tuberc Lung Dis (2000) 1.14
Pneumocystis colitis in a patient with the acquired immunodeficiency syndrome. Am J Gastroenterol (1992) 1.13
Comparison of BACTEC MYCO/F LYTIC and WAMPOLE ISOLATOR 10 (lysis-centrifugation) systems for detection of bacteremia, mycobacteremia, and fungemia in a developing country. J Clin Microbiol (2000) 1.12
Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis (1995) 1.11
[Intestinal spirochetosis in HIV infection: prevalence, isolation and morphology of spirochetes]. Dtsch Med Wochenschr (1990) 1.00
Cyanide toxicity after immersion and the hazards of dicobalt edetate. Br Med J (Clin Res Ed) (1985) 1.00
Alcoholism is associated with GALR3 but not two other galanin receptor genes. Genes Brain Behav (2006) 0.99
Knowledge of tuberculosis among drug users. Relationship to return rates for tuberculosis screening at a syringe exchange. J Subst Abuse Treat (1999) 0.99
Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med (2012) 0.99
Utility of paired BACTEC MYCO/F LYTIC blood culture vials for detection of bacteremia, mycobacteremia, and fungemia. J Clin Microbiol (2001) 0.96
Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network. Eur J Clin Microbiol Infect Dis (2005) 0.93
Cytomegalovirus pneumonia. Semin Respir Infect (1999) 0.93
The Clinical Evaluation of Cholangiograms. Ann Surg (1948) 0.92
Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol (2006) 0.91
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health. Int J Tuberc Lung Dis (1999) 0.90
Clinical features and outcomes of HIV-related cytomegalovirus pneumonia. AIDS (1997) 0.90
German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med Res (2004) 0.89
30 Years on Selected Issues in the Prevention of HIV among Persons Who Inject Drugs. Adv Prev Med (2013) 0.88
The experience of respiratory isolation for HIV-infected persons with tuberculosis. J Assoc Nurses AIDS Care (1996) 0.88
Intestinal cytomegalovirus disease in immunocompromised patients may be ruled out by search for cytomegalovirus DNA in stool samples. J Clin Microbiol (1995) 0.88
Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users. Int J STD AIDS (2006) 0.86
Hepatitis B virus genotypes and HBsAg subtypes in refugees and injection drug users in the United States determined by LiPA and monoclonal EIA. J Med Virol (2001) 0.85
Meningoencephalitis in a polar bear caused by equine herpesvirus 9 (EHV-9). Vet Pathol (2009) 0.85
Injection drug use and emerging blood-borne diseases. JAMA (1996) 0.85
Functional analysis of the yeast Ran exchange factor Prp20p: in vivo evidence for the RanGTP gradient model. Mol Genet Genomics (2001) 0.84
A focus of Rocky Mountain spotted fever within New York City. N Engl J Med (1988) 0.84
Factors associated with recent HIV testing among men who have sex with men in New York City. AIDS Behav (2014) 0.84
Drug-resistant tuberculosis: factors associated with rise in resistance in an HIV-infected urban population. Mt Sinai J Med (1994) 0.84
The incidence of HBV infection and syringe exchange programs. JAMA (1991) 0.83
[Cryptosporidia in biopsies of the gastrointestinal tract]. Pathologe (1986) 0.83
[Gastrointestinal findings in HIV infection. Clinical aspects, microbiological findings and endoscopic picture]. Dtsch Med Wochenschr (1988) 0.83
Aspergillosis in the acquired immunodeficiency syndrome. Chest (1991) 0.82
Implementation of universal directly observed therapy at a New York City hospital and evaluation of an out-patient directly observed therapy program. Int J Tuberc Lung Dis (1997) 0.82
Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection (2005) 0.82
Isospora belli infection: treatment with pyrimethamine. Ann Intern Med (1988) 0.80
Selective malabsorption and the origin of mono-rifampin-resistant Mycobacterium tuberculosis. Am J Respir Crit Care Med (1996) 0.79
Bacterial mutagenicity screening in the pharmaceutical industry. Mutat Res (2012) 0.79
Community-acquired methicillin-resistant Staphylococcus aureus infections in otolaryngology. Otolaryngol Head Neck Surg (1992) 0.79
Effects of elevated calcium on learned helplessness and brain serotonin metabolism in rats. Pharmacol Biochem Behav (1986) 0.78
[Screening and therapy of anal intraepithelial neoplasia (AIN) and anal carcinoma in patients with HIV-infection]. Dtsch Med Wochenschr (2003) 0.78
Random rapid amplification of cDNA ends (RRACE) allows for cloning of multiple novel human cDNA fragments containing (CAG)n repeats. Gene (1995) 0.78
Experience with a cross-study endpoint review committee for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (1998) 0.78
Intraoperative gamma detection of 125I-lanreotide in women with primary breast cancer. Ann Surg Oncol (1999) 0.78
Hepatitis C virus-specific immune responses in noninjecting drug users. J Viral Hepat (2012) 0.78
Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial. HIV Med (2001) 0.77
Public health and changes in illicit drug prices. Am J Public Health (2001) 0.77
Evidence for superantigen involvement in preeclampsia. Am J Reprod Immunol (2000) 0.77
Treatment of spondylodiscitis in human immunodeficiency virus-infected patients: a comparison of conservative and operative therapy. Spine (Phila Pa 1976) (2009) 0.76
Two-stage tuberculin skin testing in an HIV-infected population: a preliminary report. Mt Sinai J Med (1994) 0.76
Buspirone decreases the activity of 5-hydroxytryptamine-containing dorsal raphe neurons in-vitro. J Pharm Pharmacol (1986) 0.76
Organizational issues in conducting tuberculosis screening at a syringe exchange program. J Subst Abuse Treat (1998) 0.76
Directly observed therapy and treatment adherence. Lancet (2000) 0.75
Special problems in treating tuberculosis. Ann Intern Med (1994) 0.75
Directly observed treatment of tuberculosis. N Engl J Med (1993) 0.75
Preventing opportunistic infections in HIV-infected injection drug users. JAMA (1997) 0.75
[Comparison of the effect of 2 therapy concepts in the treatment of Pneumocystis carinii pneumonia. Cotrimoxazole for 21 days versus sequential therapy with cotrimoxazole followed by pentamidine inhalation]. Med Klin (Munich) (1990) 0.75
Drug use. Vancouver Conference Review. AIDS Care (1997) 0.75
[Gastrointestinal cytomegalovirus manifestations in AIDS]. Z Gastroenterol (1989) 0.75
Effects of dopamine and amphetamine on mouse caudate neurons recorded in vitro. Eur J Pharmacol (1986) 0.75
Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations. HIV Med (2005) 0.75
[Determinants of serum pentamidine concentration in the human]. Med Klin (Munich) (1992) 0.75
Effects of phenylpropanolamine on gastric retention in the adult rat. Brain Res Bull (1986) 0.75
[Spontaneous pneumothorax in AIDS. Observations in 10 patients]. Rofo (1990) 0.75
A new respiratory care center: model for planning and design. Respir Care (1977) 0.75
Morphine increases locus coeruleus noradrenergic neuronal activity in vitro. Eur J Pharmacol (1986) 0.75
Morphine increases the activity of midbrain dopamine neurons in vitro. Eur J Pharmacol (1985) 0.75
Outcomes of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor use in neutropenic patients infected with human immunodeficiency virus. Int J Infect Dis (1999) 0.75
Disseminated toxoplasmosis in AIDS patients--report of 16 cases. Scand J Infect Dis (1995) 0.75
Survival after 67 days of continuous hemodiafiltration in a patient with multiple system organ failure. Crit Care Med (1992) 0.75
[The clinical multiplicity of AIDS]. Verh Dtsch Ges Inn Med (1989) 0.75
[Unwanted drug side effects with pentamidine inhalation]. Med Klin (Munich) (1990) 0.75
Dermoid cyst of the spine in childhood. Orthopedics (1986) 0.75
Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing antiretroviral therapy - IDKF 13 -. German AIDS Study Group (GASG/IdKF). Eur J Med Res (1999) 0.75
Evaluation of a patient referral contact tracing programme for hepatitis B and C virus infection in drug injectors. Euro Surveill (2009) 0.75
[Pharmacologic studies with pentamidine aerosol in HIV patients]. Med Klin (Munich) (1990) 0.75
Miconazole and clobazam; a useful interaction in Dravet's syndrome? Arch Dis Child (2004) 0.75
Nursing Mirror clinical forum. 4. Easing the heartache. Nurs Mirror (1983) 0.75
Phencyclidine suppresses the activity of midbrain dopamine-containing neurons recorded from mouse brain slices in vitro. Eur J Pharmacol (1987) 0.75
[The therapy of Candida esophagitis in AIDS patients with fluconazole]. Mycoses (1990) 0.75